194 related articles for article (PubMed ID: 9375802)
1. Phytanic acid alpha-oxidation in peroxisomal disorders: studies in cultured human fibroblasts.
Verhoeven NM; Schor DS; Roe CR; Wanders RJ; Jakobs C
Biochim Biophys Acta; 1997 Oct; 1361(3):281-6. PubMed ID: 9375802
[TBL] [Abstract][Full Text] [Related]
2. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.
Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR
J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705
[TBL] [Abstract][Full Text] [Related]
3. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders.
ten Brink HJ; Schor DS; Kok RM; Poll-The BT; Wanders RJ; Jakobs C
J Lipid Res; 1992 Oct; 33(10):1449-57. PubMed ID: 1385561
[TBL] [Abstract][Full Text] [Related]
4. Phytanic acid oxidation: normal activation and transport yet defective alpha-hydroxylation of phytanic acid in peroxisomes from Refsum disease and rhizomelic chondrodysplasia punctata.
Pahan K; Khan M; Singh I
J Lipid Res; 1996 May; 37(5):1137-43. PubMed ID: 8725164
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of phytanic acid and pristanic acid in man: a review.
Verhoeven NM; Wanders RJ; Poll-The BT; Saudubray JM; Jakobs C
J Inherit Metab Dis; 1998 Oct; 21(7):697-728. PubMed ID: 9819701
[TBL] [Abstract][Full Text] [Related]
6. Phytanic acid alpha-oxidation in rat liver peroxisomes. Production of alpha-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors.
Mihalik SJ; Rainville AM; Watkins PA
Eur J Biochem; 1995 Sep; 232(2):545-51. PubMed ID: 7556205
[TBL] [Abstract][Full Text] [Related]
7. Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
Ferdinandusse S; Rusch H; van Lint AE; Dacremont G; Wanders RJ; Vreken P
J Lipid Res; 2002 Mar; 43(3):438-44. PubMed ID: 11893780
[TBL] [Abstract][Full Text] [Related]
8. Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders.
Herzog K; van Lenthe H; Wanders RJA; Vaz FM; Waterham HR; Ferdinandusse S
Mol Genet Metab; 2017 Jul; 121(3):279-282. PubMed ID: 28566232
[TBL] [Abstract][Full Text] [Related]
9. Pristanic acid beta-oxidation in peroxisomal disorders: studies in cultured human fibroblasts.
Verhoeven NM; Schor DS; Roe CR; Wanders RJ; Jakobs C
Biochim Biophys Acta; 1998 Apr; 1391(3):351-6. PubMed ID: 9555092
[TBL] [Abstract][Full Text] [Related]
10. Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders.
Kase BF; Björkhem I
Scand J Clin Lab Invest; 1996 May; 56(3):211-7. PubMed ID: 8761525
[TBL] [Abstract][Full Text] [Related]
11. Phytanic acid alpha-oxidation: decarboxylation of 2-hydroxyphytanoyl-CoA to pristanic acid in human liver.
Verhoeven NM; Wanders RJ; Schor DS; Jansen GA; Jakobs C
J Lipid Res; 1997 Oct; 38(10):2062-70. PubMed ID: 9374128
[TBL] [Abstract][Full Text] [Related]
12. Evidence against alpha-hydroxyphytanic acid as an intermediate in the metabolism of phytanic acid.
Skjeldal OH; Stokke O
Scand J Clin Lab Invest; 1988 Feb; 48(1):97-102. PubMed ID: 2464193
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction.
Poulos A; Sharp P; Fellenberg AJ; Johnson DW
Eur J Pediatr; 1988 Feb; 147(2):143-7. PubMed ID: 2452737
[TBL] [Abstract][Full Text] [Related]
14. In vivo study of phytanic acid alpha-oxidation in classic Refsum's disease and chondrodysplasia punctata.
ten Brink HJ; Schor DS; Kok RM; Stellaard F; Kneer J; Poll-The BT; Saudubray JM; Jakobs C
Pediatr Res; 1992 Nov; 32(5):566-70. PubMed ID: 1282700
[TBL] [Abstract][Full Text] [Related]
15. Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts.
Verhoeven NM; Roe DS; Kok RM; Wanders RJ; Jakobs C; Roe CR
J Lipid Res; 1998 Jan; 39(1):66-74. PubMed ID: 9469587
[TBL] [Abstract][Full Text] [Related]
16. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes.
Singh I; Pahan K; Singh AK; Barbosa E
J Lipid Res; 1993 Oct; 34(10):1755-64. PubMed ID: 7504046
[TBL] [Abstract][Full Text] [Related]
17. Human metabolism of phytanic acid and pristanic acid.
Verhoeven NM; Jakobs C
Prog Lipid Res; 2001 Nov; 40(6):453-66. PubMed ID: 11591435
[TBL] [Abstract][Full Text] [Related]
18. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Wierzbicki AS
Biochem Soc Trans; 2007 Nov; 35(Pt 5):881-6. PubMed ID: 17956237
[TBL] [Abstract][Full Text] [Related]
19. Phytanic acid: production from phytol, its breakdown and role in human disease.
van den Brink DM; Wanders RJ
Cell Mol Life Sci; 2006 Aug; 63(15):1752-65. PubMed ID: 16799769
[TBL] [Abstract][Full Text] [Related]
20. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.
Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM
Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
